CARBAGLU is the first and only FDA-approved medication indicated for the adjunctive treatment of acute hyperammonemia due to PA or MMA.
Be prepared to act quickly to identify and treat acute hyperammonemia due to PA, MMA, or NAGS deficiency, Rapid progression to a hyperammonemic crisis can occur in anyone with these disorders. FDA-approved CARBAGLU, in conjunction with standard of care, can be the key to normalizing acute high plasma ammonia levels.
CARBAGLU can be delivered to hospitals for adjunctive acute hyperammonemia therapy or to patients' homes for maintenance therapy.Get regular and STAT delivery instructions
CARBAGLU may be administered via a cup, oral syringe, nasogastric or gastrostomy tube based on patient age and condition.Review dosing and administration instructions
Help your patients access payment assistance and online resources.Access patient resources
Carbaglu® (carglumic acid) tablets for oral suspension 200mg is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as:
You are about to leave the CARBAGLU.net website and enter a website operated by an independent third party. The links to third-party websites contained on CARBAGLU.net are provided solely for your convenience. Recordati Rare Diseases does not control the opinions, claims or comments contained on any third-party website linked to CARBAGLU.net, and your activities at those websites will be governed by the policies and practices of those third parties.